^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SLC45A3 (Solute Carrier Family 45 Member 3)

    i
    Other names: SLC45A3, Solute Carrier Family 45 Member 3, Prostate Cancer Associated Protein 2, Prostate Cancer Associated Protein 6, Prostate Cancer Associated Protein 8, Prostein, PCANAP6, PRST, Prostate Cancer-Associated Protein 6, Solute Carrier Family 45, Member 3, Prostate Cancer-Associated Gene 2, Prostate Cancer-Associated Gene 6, Prostate Cancer-Associated Gene 8, PCANAP2, PCANAP8, IPCA-2, IPCA-6, IPCA-8, IPCA6
    almost2years
    MIR4435-2HG as a possible novel predictive biomarker of chemotherapy response and death in pediatric B-cell ALL. (PubMed, Front Mol Biosci)
    Finally, MIR4435-2HG overexpression, together with MRD+, are associated with poorer survival, and together with overexpression of DAPK1 and ASCL2, it could improve the risk classification of patients with normal karyotype. MIR4435-2HG is a potential predictive biomarker of treatment response and death in children with B-cell ALL.
    Journal
    |
    SLC45A3 (Solute Carrier Family 45 Member 3) • DAPK1 (Death Associated Protein Kinase 1) • ITGA6 (Integrin, alpha 6) • MIR4435-2HG (MIR4435-2 Host Gene) • ASCL2 (Achaete-Scute Family BHLH Transcription Factor 2)
    2years
    Prostein expression in human tumors: a tissue microarray study on 19,202 tumors from 152 different Tumor entities. (PubMed, Diagn Pathol)
    Our data provide a comprehensive overview on prostein expression in human cancers. Prostein is a highly sensitive prostate cancer marker occurring in > 96% of prostate cancers. Because prostein can also be expressed in various other tumor entities, classifying of a tumor mass as a prostate cancer should not be based on prostein positivity alone.
    Journal
    |
    SLC45A3 (Solute Carrier Family 45 Member 3)
    2years
    Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer. (PubMed, Virchows Arch)
    In conclusion, our results indicate that UF and MF PCa have relevant and consistent molecular differences. The analysis of an immunohistochemical panel, composed by PTEN, SPOP, SLC45A3, ETV1 and ERG, could be useful to predict outcome in MF cases.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • SPOP (Speckle Type BTB/POZ Protein) • ETV1 (ETS Variant Transcription Factor 1) • SLC45A3 (Solute Carrier Family 45 Member 3)
    |
    PTEN expression • PTEN overexpression • ERG overexpression • ETV1 overexpression
    almost3years
    Whole genome and transcriptome sequencing of a pan-cancer cohort unearths novel therapeutic avenues (AACR 2023)
    Drug screening of the corresponding PDTO showed an enhanced response to Olaparib, in contrast to cases without HRD that did not. We have used state-of-the-art analysis of WGTS to improve the detection of targets and significant biomarkers in a pan cancer cohort, including HRD, CDK12-type genomic instability, pathogenic germline mutations and potential targetable novel fusions. A robust and clinically relevant ex vivo preclinical model allowed us to validate a WGS-based classifier that detects HRD even in cancers with wildtype BRCA1/2.
    BRCA Biomarker • PARP Biomarker • Pan tumor
    |
    ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FGFR1 (Fibroblast growth factor receptor 1) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • RAD51 (RAD51 Homolog A) • EP300 (E1A binding protein p300) • SLC45A3 (Solute Carrier Family 45 Member 3)
    |
    HRD • FGFR1 amplification • ALK fusion • BRCA wild-type
    |
    Lynparza (olaparib)
    almost3years
    SLC45A3 Serves as a Potential Therapeutic Biomarker to Attenuate White Matter Injury After Intracerebral Hemorrhage. (PubMed, Transl Stroke Res)
    Further experiments verified overexpression of SLC45A3 ameliorated brain injury after ICH. Therefore, SLC45A3 might serve as a candidate therapeutic biomarker for ICH-induced WMI, and overexpression of it may be a potential approach for injury attenuation.
    Journal
    |
    SLC45A3 (Solute Carrier Family 45 Member 3)
    almost3years
    Transcriptomic profiling and genomic rearrangement landscape of Nigerian prostate cancer. (PubMed, Prostate)
    Less frequent ETS fusion events other than TMPRSS2-ERG such as TMPRSS2-ETV5 and non-ETS fusion events such as SLC45A3-SKIL may be more common in PCa in Nigerian men. This study provides useful working transcriptomic signatures that characterize oncogenic states representative of specific gene fusion events in PCa from Nigerian men.
    Journal
    |
    ERG (ETS Transcription Factor ERG) • ETV5 (ETS Variant Transcription Factor 5) • SLC45A3 (Solute Carrier Family 45 Member 3)
    |
    TMPRSS2-ERG fusion
    3years
    Erythroblast transformation-specific transcription factor fusions in prostate cancer. (ASCO-GU 2023)
    In addition to TMPRSS2:ERG, the Oncomap ExTra assay identified several low frequency ETS fusions, all of which could be used to assist patients and physicians to select appropriate treatments. The identification of ETS fusions appears to be limited when using only DNA sequencing. Oncomap ExTra RNA analysis identified 66 additional fusions, representing almost 30% of those present, not identified by whole-exome DNA sequencing, suggesting RNA plus DNA assays detect fusions more reliably than DNA-only assays.
    ERG (ETS Transcription Factor ERG) • ETV1 (ETS Variant Transcription Factor 1) • SLC45A3 (Solute Carrier Family 45 Member 3)
    |
    TMPRSS2-ERG fusion
    |
    Oncomap™ ExTra test
    3years
    Systematic Analysis of Cellular Signaling Pathways and Therapeutic Targets for SLC45A3:ERG Fusion-Positive Prostate Cancer. (PubMed, J Pers Med)
    Interestingly, PDGFRA and PDGFRB were the most frequently predicted therapeutic targets, and imatinib targeted both genes. In this study, we provide extensive information on cellular signaling pathways involved in S:E fusion-positive prostate cancer and also suggest therapeutic methods.
    Journal
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ERG (ETS Transcription Factor ERG) • TGFB1 (Transforming Growth Factor Beta 1) • SLC45A3 (Solute Carrier Family 45 Member 3)
    |
    imatinib
    over3years
    Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations. (PubMed, Cancer Res Commun)
    Further, ALK fusions similar to lung cancer are an occasional driver in prostate cancer. Our data suggest that ALK-directed therapies could be an option in selected patients with advanced prostate cancer.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • SLC45A3 (Solute Carrier Family 45 Member 3)
    |
    ALK fusion
    over3years
    Optical Genome Mapping for Enhanced Structural Variation Detection in a Case of Glioblastoma (CAP 2022)
    R.B. Kolhe is a consultant with Illumina, Bionano, Agena, QIAGEN, Perkin Elmer, PGDx, and Cepheid, and received grant or research support from Perkin Elmer and Bionano.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MDM4 (The mouse double minute 4) • CDK6 (Cyclin-dependent kinase 6) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • PIM1 (Pim-1 Proto-Oncogene) • CCND3 (Cyclin D3) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • PDE4DIP (Phosphodiesterase 4D Interacting Protein) • SLC45A3 (Solute Carrier Family 45 Member 3) • CNOT3 (CCR4-NOT Transcription Complex Subunit 3) • KLK2 (Kallikrein-related peptidase 2) • TFEB (Transcription Factor EB 2)